1.55
price down icon6.91%   -0.115
 
loading
Schlusskurs vom Vortag:
$1.665
Offen:
$1.64
24-Stunden-Volumen:
52,692
Relative Volume:
1.54
Marktkapitalisierung:
$9.47M
Einnahmen:
$93.76M
Nettoeinkommen (Verlust:
$-13.68M
KGV:
-0.5894
EPS:
-2.63
Netto-Cashflow:
$8.77M
1W Leistung:
-6.91%
1M Leistung:
-13.61%
6M Leistung:
-37.11%
1J Leistung:
-38.74%
1-Tages-Spanne:
Value
$1.53
$1.66
1-Wochen-Bereich:
Value
$1.53
$1.72
52-Wochen-Spanne:
Value
$1.3001
$3.45

Aytu Biopharma Inc Stock (AYTU) Company Profile

Name
Firmenname
Aytu Biopharma Inc
Name
Telefon
(720) 437-6580
Name
Adresse
7900 E. UNION AVENUE, DENVER
Name
Mitarbeiter
102
Name
Twitter
@aytubioscience
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
AYTU's Discussions on Twitter

Vergleichen Sie AYTU mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AYTU
Aytu Biopharma Inc
1.55 9.47M 93.76M -13.68M 8.77M -2.63
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
171.43 77.34B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.55 43.18B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.53 42.89B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.83 19.07B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
127.01 13.49B 612.78M -86.37M -62.91M -0.87

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-03-30 Eingeleitet Cantor Fitzgerald Overweight
2020-05-29 Eingeleitet H.C. Wainwright Buy

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

pulisher
Feb 06, 2025

Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire

Feb 06, 2025
pulisher
Feb 05, 2025

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - ACCESS Newswire

Feb 05, 2025
pulisher
Feb 05, 2025

Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan

Feb 05, 2025
pulisher
Feb 03, 2025

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire

Feb 03, 2025
pulisher
Jan 29, 2025

Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire

Jan 29, 2025
pulisher
Jan 27, 2025

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 26, 2025

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 18, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St

Jan 18, 2025
pulisher
Jan 06, 2025

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - AccessWire

Jan 06, 2025
pulisher
Jan 06, 2025

Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World

Jan 02, 2025
pulisher
Dec 27, 2024

An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com

Dec 27, 2024
pulisher
Dec 27, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St

Dec 27, 2024
pulisher
Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia

Dec 14, 2024
pulisher
Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 06, 2024

Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World

Dec 06, 2024
pulisher
Dec 05, 2024

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Dec 05, 2024
pulisher
Dec 03, 2024

Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan

Dec 03, 2024
pulisher
Dec 03, 2024

Aytu BioPharma Disclosure Notification - AccessWire

Dec 03, 2024
pulisher
Dec 03, 2024

Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance

Dec 03, 2024
pulisher
Nov 22, 2024

Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 18, 2024

Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St

Nov 18, 2024
pulisher
Nov 16, 2024

Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St

Nov 15, 2024
pulisher
Nov 14, 2024

Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500

Nov 13, 2024
pulisher
Nov 08, 2024

Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia

Nov 08, 2024
pulisher
Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail

Nov 05, 2024
pulisher
Nov 05, 2024

Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR

Nov 05, 2024
pulisher
Nov 01, 2024

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia

Nov 01, 2024
pulisher
Oct 29, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 23, 2024

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

Oct 23, 2024
pulisher
Oct 22, 2024

AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com

Oct 22, 2024
pulisher
Oct 14, 2024

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire

Oct 14, 2024
pulisher
Oct 11, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia

Oct 11, 2024
pulisher
Oct 09, 2024

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 06, 2024

Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle

Oct 06, 2024

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$31.57
price up icon 0.57%
$11.52
price down icon 3.76%
$88.71
price down icon 2.41%
$122.62
price down icon 18.53%
$10.73
price down icon 1.56%
$127.01
price down icon 0.09%
Kapitalisierung:     |  Volumen (24h):